JPWO2023110918A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023110918A5 JPWO2023110918A5 JP2024535534A JP2024535534A JPWO2023110918A5 JP WO2023110918 A5 JPWO2023110918 A5 JP WO2023110918A5 JP 2024535534 A JP2024535534 A JP 2024535534A JP 2024535534 A JP2024535534 A JP 2024535534A JP WO2023110918 A5 JPWO2023110918 A5 JP WO2023110918A5
- Authority
- JP
- Japan
- Prior art keywords
- pmhc
- binding
- domain
- antigen
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289380P | 2021-12-14 | 2021-12-14 | |
| US63/289,380 | 2021-12-14 | ||
| US202263317256P | 2022-03-07 | 2022-03-07 | |
| US63/317,256 | 2022-03-07 | ||
| US202263328417P | 2022-04-07 | 2022-04-07 | |
| US63/328,417 | 2022-04-07 | ||
| PCT/EP2022/085689 WO2023110918A1 (en) | 2021-12-14 | 2022-12-13 | Dual mhc-targeting t cell engager |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024546875A JP2024546875A (ja) | 2024-12-26 |
| JPWO2023110918A5 true JPWO2023110918A5 (https=) | 2025-12-23 |
| JP2024546875A5 JP2024546875A5 (https=) | 2025-12-23 |
Family
ID=84887466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535534A Pending JP2024546875A (ja) | 2021-12-14 | 2022-12-13 | 二連型ｍｈｃ標的化ｔ細胞エンゲージャー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250002586A1 (https=) |
| EP (1) | EP4448570A1 (https=) |
| JP (1) | JP2024546875A (https=) |
| KR (1) | KR20240116828A (https=) |
| AU (1) | AU2022413444A1 (https=) |
| CA (1) | CA3240046A1 (https=) |
| MX (1) | MX2024007473A (https=) |
| WO (1) | WO2023110918A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025210181A1 (en) * | 2024-04-04 | 2025-10-09 | Cdr-Life Ag | Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| AU2003264009A1 (en) | 2002-08-15 | 2004-03-03 | Epitomics, Inc. | Humanized rabbit antibodies |
| JP3803790B2 (ja) | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| EP1651659A4 (en) | 2003-08-07 | 2008-09-17 | Epitomics Inc | METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES |
| DE602004030811D1 (de) | 2003-10-16 | 2011-02-10 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
| JP5139800B2 (ja) | 2004-06-03 | 2013-02-06 | ノビミューン エスアー | 抗ｃｄ３抗体およびその使用方法 |
| WO2007101661A1 (en) | 2006-03-09 | 2007-09-13 | F.Hoffmann-La Roche Ag | Anti-drug antibody assay |
| US20100015142A1 (en) | 2006-12-21 | 2010-01-21 | Macrogenics Inc. | Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity |
| IN2009DN05758A (https=) | 2007-03-12 | 2015-07-24 | Esbatech Ag | |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| KR20170036814A (ko) | 2007-05-21 | 2017-04-03 | 앨더바이오 홀딩스 엘엘씨 | 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체 |
| KR101530723B1 (ko) | 2007-06-25 | 2015-06-22 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화 |
| US20090074780A1 (en) | 2007-06-25 | 2009-03-19 | David Urech | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| CN104004094B (zh) | 2008-06-25 | 2017-09-22 | 艾斯巴技术-诺华有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| PL3241843T3 (pl) | 2008-06-25 | 2021-12-27 | Novartis Ag | Optymalizacja rozpuszczalności cząsteczek immunowiążących |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| CA2902739C (en) | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| CA2939080A1 (en) | 2014-02-11 | 2015-08-20 | Genzyme Corporation | Assays for detecting the presence or amount of an anti-drug antibody |
| CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| EP3602056A1 (en) | 2017-03-31 | 2020-02-05 | Ablynx N.V. | Improved immunogenicity assays |
| SG11202000025SA (en) * | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| RU2020135920A (ru) | 2018-04-05 | 2022-05-05 | Новартис Аг | Триспецифические связывающие молекулы против форм рака и пути их применения |
| CN118852456A (zh) * | 2019-05-29 | 2024-10-29 | Cue生物制药股份有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| EP4025908A4 (en) | 2019-09-05 | 2023-07-19 | Adverum Biotechnologies, Inc. | ANTI-DRUG ANTIBODY TEST |
| NL2024375B1 (en) * | 2019-12-04 | 2021-08-31 | Apo T B V | Methods and means for attracting immune effector cells to tumor cells. |
| KR20220113492A (ko) * | 2019-12-11 | 2022-08-12 | 몰리큘라 파트너스 아게 | 변경된 표면 잔기를 갖는 설계된 안키린 반복 도메인 |
| EP4304725A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| US11912771B2 (en) | 2021-03-09 | 2024-02-27 | Cdr-Life Ag | MAGE-A4 peptide-MHC antigen binding proteins |
-
2022
- 2022-12-13 KR KR1020247023302A patent/KR20240116828A/ko active Pending
- 2022-12-13 WO PCT/EP2022/085689 patent/WO2023110918A1/en not_active Ceased
- 2022-12-13 MX MX2024007473A patent/MX2024007473A/es unknown
- 2022-12-13 AU AU2022413444A patent/AU2022413444A1/en active Pending
- 2022-12-13 EP EP22839165.2A patent/EP4448570A1/en active Pending
- 2022-12-13 JP JP2024535534A patent/JP2024546875A/ja active Pending
- 2022-12-13 CA CA3240046A patent/CA3240046A1/en active Pending
-
2024
- 2024-06-06 US US18/736,330 patent/US20250002586A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025109759A5 (https=) | ||
| US11401337B2 (en) | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function | |
| AU2016336866B2 (en) | Multivalent Fv antibodies | |
| JP2025065142A5 (https=) | ||
| JP2020186248A5 (https=) | ||
| EP4013792A1 (en) | Immunostimulatory multimeric binding molecules | |
| US20220372142A1 (en) | Multimeric antibodies with enhanced selectivity for cells with high target density | |
| JP2020500510A5 (https=) | ||
| CA3173414A1 (en) | Pd-1 agonist multimeric binding molecules | |
| CN119032104A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| WO2017107885A1 (zh) | 抗人程序性死亡受体1抗体及其制备方法和用途 | |
| JP2024507693A (ja) | 二重特異性抗体 | |
| JP2023530083A (ja) | Ｈｌａ－ｇ及び別の抗原に対して結合特異性を有する二重特異性免疫細胞エンゲージャー | |
| JP2021524451A5 (https=) | ||
| JPWO2023034922A5 (https=) | ||
| CN111201242A (zh) | 不对称异二聚fc-scfv融合抗globo h及抗cd3双特异性抗体及其在癌症治疗上的用途 | |
| JPWO2021139758A5 (https=) | ||
| CN114075287B (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| JPWO2020071554A5 (https=) | ||
| KR20230072536A (ko) | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 | |
| JPWO2023110918A5 (https=) | ||
| CN115397833A (zh) | 多聚体IgA抗体的制造方法与多特异性多聚体IgA抗体 | |
| CN114685659B (zh) | Cd22特异性人源化抗体及利用其的嵌合抗原受体 | |
| JPWO2022190009A5 (https=) | ||
| US20250312452A1 (en) | Antibody targeting claudin18.2 and its applications |